FDA to Streamline Antibiotic Development; Combat Resistance

The FDA is proposing four drug development approaches that it hopes will help streamline and incentivize development of drugs for patients with antibacterial drug-resistant infections. The guidance, released in Q&A format, could be a game-changer in the agency’s war against drug-resistant bacterial diseases and perk drugmaker interest in investing more in antibacterial research.
Washington Drug Letter